Pharmaceutical impurity identification: A case study using a multidisciplinary approach

Journal of Pharmaceutical Sciences

Volumn 93, Issue 9, 2004, Pages 2296-2309

  Alsante, Karen M ^a   Boutros, Peter ^a,b   Couturier, Michel A ^a   Friedmann, Robert C ^a   Harwood, Jeffrey W ^a   Horan, George J ^a   Jensen, Andrew J ^a   Liu, Qicai ^a   Lohr, Linda L ^a   Morris, Ronald ^a   Raggon, Jeffrey W ^a   Reid, George L ^a   Santafianos, Dinos P ^a   Sharp, Thomas R ^a   Tucker, John L ^a   Wilcox, Glenn E ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Vitasal Inc   (United States)

Author keywords

Case study; Multidisciplinary approach; Pharmaceutical impurity identification

Indexed keywords

SULFONYLUREA DERIVATIVE;

ACIDITY; ANALYTIC METHOD; ARTICLE; CASE STUDY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DEGRADATION; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG PURITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; SOLID PHASE EXTRACTION; SPECTROSCOPY; VALIDATION PROCESS;

EID: 4344659257     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20120     Document Type: Article

References (15)

1. ICH Steering Committee. 2002. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use-Impurities in new drug substances. ICH Steering Committee, March 30, 1995.
2. Federal Register. 2003. 68:6924-6925.
3. Roberts JK, Smith RJ. 1994. Use of liquid chromatography-nuclear magnetic resonance spectroscopy for the identification of impurities in drug substances. J Chromatogr A 677:385-389.
4. Lehr GJ, Barry TL, Petzinger G, Hanna GM, Zito SW. 1999. Isolation and identification of process impurities in trimethoprim drug substance by high-performance liquid chromatography, atmospheric pressure chemical ionization liquid chromatography/mass spectrometry and nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 19:373-389.
5. Lindon JC, Nicholson JK, Wilson ID. 2000. Directly coupled HPLC-NMR and HPLC-NMR-MS in pharmaceutical research and development. J Chromatgr B Biomed Sci Appl 748:233-258.
6. Ryan TW. 1998. Identification of four process-related impurities in the bulk drug butalbital using HPLC-UV photodiode array detection, particle beam MS, and NMR. Anal Lett 31:2447-2456.
7. Hamdan M. 1997. Pharmaceutical applications of liquid chromatography, capillary electrophoresis coupled to mass spectrometry. Process Control Qual 10:113-127.
8. Alsante KM, Hatajik TD, Lohr LL, Sharp TR. 2001. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates, Part I. Am Pharm Rev 4:70-78.
9. Lohr LL, Sharp TR, Alsante KM, Hatajik TD. 2001. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates, Part II. The role of NMR and mass spectrometry. Am Pharm Rev 4:104-113.
10. Urban FJ, Jasys VJ, Raggon JW, Buzon RA, Hill PD, Eggler JF, Weaver JD. 2003. Process research on 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1- hydroxy-1-methyl-ethyl)-furan-2-sulphonyl urea, an anti-inflammatory agent. Synthet Commun 33: 2031-2045.
11. McLafferty F, Turecek F. 1993. Interpretation of mass spectra, 4th ed. Mill Valley, CA: University Science Books, pp 37-38.
12. Bai Y, Milne JS, Mayne L, Englander SW. 1993. Primary structure effects on peptide group hydrogen exchange. Proteins Struct Funct Genet 17: 75-86.
13. Urban FJ, Jasys VJ. 2000. U.S. Patent 6 022 984.
14. 3-Furoic acid was manufactured by Eastman Chemical Company, 100 North Eastman Road, P.O. Box 511, Kingsport, TN 37662. Details of the synthesis are unknown.
15. Ritter JJ, Minieri PP. 1948. A new reaction of nitriles. I. Amides from alkenes and mononitriles. J Am Chem Soc 70:4045-4048.